Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00204295
Status:
UNKNOWN
Last Update Posted:
2006-09-14
First Post:
2005-09-13
Brief Title:
Study on Amino Acid Uptake in Brain Tumors
Sponsor:
University Hospital Muenster
Organization:
University Hospital Muenster
Study Overview
Official Title:
Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-2-F-18Fluorethyl-L-Tyrosin FET
Status:
UNKNOWN
Status Verified Date:
2006-09
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the uptake of the amino acid O-2-F-18Fluorethyl-L-tyrosin FET in human brain tumors using positron emission tomography A comparison to MRI and histopathological samples is used
Detailed Description:
Radioactively labelled amino acids have been used for years to delineate primary brain tumors and for the early detection of tumor recurrence Positron emission tomography studies indicate that the extent of amino acid uptake correlates to the true histological extent of gliomas Recently a fluorine-18 labelled amino acid has been introduced O-2-F-18Fluorethyl-L-tyrosin FET which is suitable for routine use in brain tumor patients There is evidence that this amino acid is transported into brain and brain tumors by the amino acid transport of the L-type The cDNA of this L-transporter has recently been cloned and has been shown to be identical to the light chain of the 4F2-antigen CD98 which has previously been described as marker of cell growth and proliferation
The heavy chain of this heterodimer is known to modulate integrins which are thought to play a fundamental role in glioma invasion
Besides the evaluation of the diagnostic capability of FET in brain tumors a comparison of FET uptake in vivo and CD98 expression ex-vivo is performed with tissue slices as available after routine surgery in glioma patients
The heavy chain of this heterodimer is known to modulate integrins which are thought to play a fundamental role in glioma invasion
Besides the evaluation of the diagnostic capability of FET in brain tumors a comparison of FET uptake in vivo and CD98 expression ex-vivo is performed with tissue slices as available after routine surgery in glioma patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None